Income StatementBalance SheetCash FlowSegments
ALM

Alamar Biosciences, Inc. Common Stock Income Statement

Revenue, expenses, and profitability over time

Based on the Q1 2026 filing.

Total Revenue$26.0MGross Profit$14.5MOperating Income-$12.3MNet Income-$21.3MEps Diluted$-1.74
Latest FilingQ1 2026
Report Date2026-05-08

Operating Expenses

MetricQ1 '25Q1 '26
Other Operating Expense, Net$154.0K-$236.0K
Research and development$8.3M$13.0M
Selling, general and administrative$6.6M$13.8M
Total operating expenses$14.9M$26.8M

Earnings Per Share

MetricQ1 '25Q1 '26
Basic earnings per share$-0.68$-1.74
Diluted earnings per share$-0.68$-1.74
Weighted-average shares, basic11.3M12.3M
Weighted-average shares, diluted11.3M12.3M

Operating Income

MetricQ1 '25Q1 '26
Gross profit$6.4M$14.5M
Operating income-$8.6M-$12.3M

Income Before Tax

MetricQ1 '25Q1 '26
Income before income taxes-$7.7M-$20.9M

Tax

MetricQ1 '25Q1 '26
Income tax expense—$464.0K

Other Income & Expense

MetricQ1 '25Q1 '26
Interest expense$46.0K$223.0K

Net Income

MetricQ1 '25Q1 '26
Net income-$7.7M-$21.3M

Cost of Revenue

MetricQ1 '25Q1 '26
Total cost of revenue$6.7M$11.6M

Revenue

MetricQ1 '25Q1 '26
Total revenue$13.1M$26.0M

Other

MetricQ1 '25Q1 '26
Interest Income Operating$786.0K$539.0K
Loss On Remeasurement Of Convertible Notes—$8.6M